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TRIS-QUARTERNARY AMMONIUM SALTS 
AND METHODS FOR MODULATING 
NEURONAL NICOTINIC ACETYLCHOLINE 
RECEPTORS 
FIELD OF THE INVENTION 
The invention relates to tris-quatemary ammonium salts 
and their use in modulating nicotinic acetylcholine receptors. 
10 
BACKGROUND OF THE INVENTION 
S(—)-nicotine (N IC) activates presynaptic andpostsynaptic 
neuronal nicotinic receptors that evoke the release of neu 
2 
these neurotransmitter systems. NIC facilitates neurotrans 
mitter release from nerve terminals. 
The structural and functional diversity of central nervous 
system nicotinic receptors has stimulated a great deal of inter 
est in developing novel, subtype-selective agonists and/or 
antagonists. Some of these agonists are currently being evalu 
ated in clinical trials for cognitive enhancement and neuro 
protective effects, potentially bene?cial for disease states 
such as AlZheimer’s and Parkinson’s disease. 
SUMMARY OF INVENTION 
In one embodiment, compounds corresponding to the fol 
loWing structure are provided. 
(I) 
to // 
rotransmitters from presynaptic terminals and that modulate 25 
the depolariZation state of the postsynaptic neuronal mem 
brane, respectively. Thus, nicotine produces its effect by 
binding to a family of ligand-gated ion channels, stimulated 
by acetylcholine (ACh) or nicotine Which causes the ion 
channel to open and cations to ?ux With a resulting rapid 30 
(millisecond) depolarization of the target cell. 
Neuronal nicotinic receptors are composed of tWo types of 
subunits, 0t and [3, and assemble as heteromeric receptors With 
the general stoichiometry of 2a and 3[3 or as homomeric 
receptors With 5a subunits. Nine subtypes of the ot subunit 
(a2 to (x10) and three subtypes of the [3 unit ([32 to [34) are 
found in the central nervous system. The mo st common nico 
tinic receptor subtype in the brain is composed of tWo (X4 and 
three [32 subunits, i.e., (X462. These subunits display different, 
but overlapping, patterns of expression in the brain. Examples 
of heteromeric receptor subtypes include (X462, (X362, (X3 [34, 
(X662, (x40t5[32, (x60t5[32, (x40t6[32, (x4[32[34, (x3[32[34, and 
others. The predominant homomeric subtype includes (x7, but 
other combinations have also been proposed. 
For the most part, the actual subunit compositions and 
stoichiometries of nicotinic receptors in the brain remain to 
be elucidated. Thus, neuronal nicotinic receptor subtype 
diversity originates from differences in the amino acid 
sequence at the subunit level and from the multiple combina 
tions of assemblies of subunits into functional receptor pro 
teins, Which affords a Wide diversity of pharmacological 
speci?city. 
In spite of the extensive diversity in neuronal nicotinic 
receptor messenger RNA expression, only a limited number 
of tools are available to study the pharmacology of native 
receptors. Radioligands are used in many studies. [3H]NIC 
appears to label the same sites in the brain as [3H]ACh. It has 
been estimated that over 90% of [3H]NIC binding in the brain 
is due to association With the heteromeric receptor that is 
composed of (X4 and [32 subunits. Also abundant in the central 
nervous system are the homomeric receptors labeled by [3 H] 
methyllycaconitine (MLA), Which has high af?nity for the (X7 
nicotinic receptor subtype. Nicotinic receptor subtypes can 
be studied using functional assays, such as NIC-evoked neu 
rotransmitter release (e.g., [3H]dopamine (DA) release, [3 H] 
norepinephrine (NE) release, [3H]serotonin (5-HT) release, 
[3 H] gamma-aminobutyric acid (GABA) release and [3 H] 
glutamate release) from superfused rat brain slices. Nicotinic 
receptors are located in the cell body and terminal areas of 
45 
50 
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The three side chains attached to the phenyl ring may be 
connected to the l, 2, and 3 positions; the l, 2, and 4 
positions; or the l, 3 and 5 positions of the phenyl ring. 
The values for ml, m2 and m3 are each independently 0, l, 2, 
3, 4 or 5. 
The values for n1, n2, and n3 are each independently l, 2, 3, 
4 or 5. 
X19, X29, and X39 are each independently an organic or 
inorganic anion. 
L1, L2 and L3 are each independently chosen from the group 
consisting of 4CH24CH2i, cis iCH:CHi, trans 
iCH:CHi, iCECi, %H2iSi, iSiCHZi, 
iSeiCHzi, iCHZiSei, %H2A)i, 
iO%H2i, iCHziNHi, iNHiCHzi, %H2i 
NRi Where R is a branched or straight chain alkyl group 
of one to four carbons, iNRiCHZi Where R is a 
branched or straight chain alkyl group of one to four car 
bons, 4CH:Ni, iN:CHi, and iN:Ni. 
R1, R2, and R3 are each independently ?ve or six membered 
nitrogen containing rings as shoWn in formulas (IIA) and 
(IIB). 
(HA) 
(IIB) 
Al is carbon or nitrogen, provided that When A1 joins a ring 
atom With an unsaturated bond or is a nitrogen, R9 is ab sent, 
and When A1 joins a ring atom an unsaturated bond and is 
a nitrogen, both R4 and R9 are absent. 
US 8,299,253 B2 
3 
A2 is carbon or nitrogen, provided that When A2 joins a ring 
atom an unsaturated bond or is a nitrogen, R10 is absent, 
and When A2 joins a ring atom an unsaturated bond and is 
a nitrogen, both R5 and R10 are absent. 
A3 is carbon or nitrogen, provided that When A3 joins a ring 
atom an unsaturated bond or is a nitrogen, R11 is absent, 
and When A3 joins a ring atom an unsaturated bond and is 
a nitrogen, both R6 and R1 l are absent. 
A4 is carbon or nitrogen; provided that When A4 joins a ring 
atom an unsaturated bond or is a nitrogen, R12 is absent, 
and When A4 joins a ring atom an unsaturated bond and is 
a nitrogen, both R7 and R12 are absent. 
A5 is carbon or nitrogen, provided that When A5 joins a ring 
atom an unsaturated bond or is a nitrogen, R13 is absent, 
and When A5 joins a ring atom an unsaturated bond and is 
a nitrogen, both R8 and R13 are absent. 
A6 is carbon or nitrogen, provided that When A6 joins a ring 
atom an unsaturated bond or is a nitrogen, R19 is absent, 
and When A6 joins a ring atom an unsaturated bond and is 
a nitrogen, both R15 and R19 are absent. 
A7 is carbon or nitrogen, provided that When A7 joins a ring 
atom an unsaturated bond or is a nitrogen, R20 is absent, 
and When A7 joins a ring atom an unsaturated bond and is 
a nitrogen, both R16 and R20 are absent. 
A8 is carbon or nitrogen, provided that When A8 joins a ring 
atom an unsaturated bond or is a nitrogen, R21 is absent, 
and When A8 joins a ring atom an unsaturated bond and is 
a nitrogen, both R17 and R21 are absent. 
A9 is carbon or nitrogen, provided that When A9 joins a ring 
atom an unsaturated bond or is a nitrogen, R22 is absent, 
and When A9 joins a ring atom an unsaturated bond and is 
a nitrogen, both R18 and R22 are absent. 
R14 or R23 is absent When any of the bonds to the ammonium 
nitrogen is unsaturated, and R14 or R23 is a straight chain or 
branched alkyl group of four carbons or feWer When all of 
the bonds to the ammonium nitrogen are saturated. 
R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ R12’ and R13 or R15’ R16, R17’ 
R18, R19, R20, R21, and R22, When present, are each inde 
pendently selected from hydrogen; alkyl; substituted alkyl; 
cycloalkyl; substituted cycloalkyl; alkenyl; substituted alk 
enyl; alkynyl; substituted alkynyl; aryl; substituted aryl; 
alkylaryl; substituted alkylaryl; arylalkyl; substituted ary 
lalkyl; arylalkenyl; substituted arylalkenyl; arylalkynyl; 
substituted arylalkynyl; heterocyclic; substituted heterocy 
clic; halo; cyano; nitro; SOY1, SOZYI, SOZOYl or 
SO2NHYl, where Y1 is selected from hydrogen, loWer 
alkyl, alkenyl, alkynyl or aryl, and where Y1 is not hydro 
gen in SOYl and if Y1 is alkenyl or alkynyl, the site of 
unsaturation is not conjugated With a heteroatom; COY2, 
Where Y2 is selected from hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkoxy, alkenyl, 
substituted alkenyl, alkynyl, substituted alkynyl, aryl, sub 
stituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, 
substituted arylalkyl, arylalkenyl, substituted arylalkenyl, 
arylalkynyl, substituted arylalkynyl, heterocyclic, or sub 
stituted heterocyclic, and Where if Y2 comprises alkenyl or 
alkynyl, the site of unsaturation is not conjugated With the 
carbonyl group; OY3 , Where Y3 is selected from hydrogen, 
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, 
aryl, substituted aryl, alkylaryl, substituted alkylaryl, ary 
lalkyl, substituted arylalkyl, arylalkenyl, substituted aryla 
lkenyl, arylalkynyl, substituted arylalkynyl, acyl, substi 
tuted acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or 
substituted heterocyclic, Where if Y3 comprises alkenyl or 
alkynyl, the site of unsaturation is not conjugated With the 
oxygen; NY4Y5, Where Y4 and Y5 are each independently 
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4 
selected from hydrogen, alkyl, substituted alkyl, 
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alk 
enyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted ary 
lalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, 
substituted arylalkynyl, acyl, substituted acyl, alkylsulfo 
nyl, arylsulfonyl, heterocyclic, or substituted heterocyclic, 
Where if Y4 or Y5 comprises alkenyl or alkynyl, the site of 
unsaturation is not conjugated With the nitrogen; SY6, 
Where Y6 is selected from hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substi 
tuted alkenyl, alkynyl, substituted alkynyl, aryl, substituted 
aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted 
arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, 
substituted arylalkynyl, heterocyclic, or substituted hetero 
cyclic, and Where if Y6 comprises alkenyl or alkynyl, the 
site of unsaturation is not conjugated With the sulfur; or R4 
and R5 together WithAl and A2, or R5 and R6 together With 
A2 and A3, or R15 and R16 together With A6 and A7, or R16 
and R17 together WithA7 andA8 independently form a three 
to eight member cycloalkane, substituted cycloalkane, 
cycloalkene, substituted cycloalkene, aryl, substituted 
aryl, heterocycle With one to three hetero atoms in the ring, 
or substituted heterocycle With one to three hetero atoms in 
the ring. 
In another embodiment, a composition is provided com 
prising a pharmaceutically acceptable carrier and a com 
pound as described above. 
In another embodiment, a method is provided for selec 
tively modulating the function of a nicotinic acetylcholine 
receptor comprising administering a therapeutically effective 
amount of a compound as described above to a mammalian 
subject in need thereof. 
In another embodiment, a method is provided for prevent 
ing and/ or treating a central nervous system associated disor 
der comprising administering a therapeutically effective 
amount of a compound as described above to a mammalian 
subject in need thereof. 
In another embodiment, a method is provided for prevent 
ing and/or treating substance use and/or abuse comprising 
administering a therapeutically effective amount of a com 
pound as described above to a mammalian subject in need 
thereof. 
In another embodiment, a method is provided for prevent 
ing and/ or treating gastrointestinal tract disorders comprising 
administering a therapeutically effective amount of a com 
pound as described above to a mammalian subject in need 
thereof. 
Other methods, features and advantages of the present 
invention Will be or become apparent to one With skill in the 
art upon examination of the folloWing detailed descriptions. It 
is intended that all such additional methods, features and 
advantages be included Within this description, be Within the 
scope of the present invention, andbe protected by the accom 
panying claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shoWs concentration-response curves for GZ551A 
in each four subtypes of nicotinic receptor (a462, 0662, 
0664 and (X7) expressed in Xenopus oocyles. 
FIG. 2 shoWs concentration-response curves for GZ551B 
in each four subtypes of nicotinic receptor (a462, 0662, 
0664 and (X7) expressed in Xenopus oocyles. 
FIG. 3 shoWs concentration-response curves for GZ558C 
in each four subtypes of nicotinic receptor (a462, 0662, 
0664 and (X7) expressed in Xenopus oocyles. 
US 8,299,253 B2 
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FIG. 4 shows the inhibitory response of the (X7 nicotinic 
receptor subtype expressed in Xenopus oocyles to 1.0 mM 
analog concentration for 17 analogs co-applied With 60 mM 
acetylcholine (?lled bars), as Well as recovery from analog 
induced inhibition following Washing of the preparation 
(open bars). 
DETAILED DESCRIPTION OF INVENTION 
Before the present compositions and methods are 
described, it is to be understood that the invention is not 
limited to the particular methodologies, protocols, assays, 
and reagents described, as these may vary. It is also to be 
understood that the terminology used herein is intended to 
describe particular embodiments of the present invention, and 
is in no Way intended to limit the scope of the present inven 
tion as set forth in the appended claims. 
It must be noted that as used herein and in the appended 
claims, the singular forms “a,” “an,” and “the” include plural 
references unless the context clearly dictates otherwise. 
Unless de?ned otherWise, all technical and scienti?c terms 
used herein have the same meanings as commonly under 
stood by one of ordinary skill in the art to Which this invention 
belongs. All publications cited herein are incorporated herein 
by reference in their entirety for the purpose of describing and 
disclosing the methodologies, reagents, and tools reported in 
the publications that might be used in connection With the 
invention. Nothing herein is to be construed as an admission 
that the invention is not entitled to antedate such disclosure by 
virtue of prior invention. 
The term “nicotinic acetylcholine receptor” refers to the 
endogenous acetylcholine receptor having binding sites for 
acetylcholine Which also bind to nicotine. The term “nicotinic 
acetylcholine receptor” includes the term “neuronal nicotinic 
acetylcholine receptor.” 
The terms “subtype of nicotinic acetylcholine receptor,” 
and “nicotinic acetylcholine receptor subtype” refer to vari 
ous subunit combinations of the nicotinic acetylcholine 
receptor, and may refer to a particular homomeric or hetero 
meric complex, or multiple homomeric or heteromeric com 
plexes. 
The term “agonist” refers to a substance Which interacts 
With a receptor and increases or prolongs a physiological 
response (i.e. activates the receptor). 
The term “partial agonist” refers to a substance Which 
interacts With and activates a receptor to a lesser degree than 
an agonist. 
The term “antagonist” refers to a substance Which interacts 
With and decreases the extent or duration of a physiological 
response of that receptor. 
The terms “disorder,” “disease,” and “condition” are used 
inclusively and refer to any status deviating from normal. 
The term “central nervous system associated disorders” 
includes any cognitive, neurological, and mental disorders 
causing aberrant or pathological neural signal transmission, 
such as disorders associated With the alteration of normal 
neurotransmitter release in the brain. 
The term “loWer alkyl” refers to straight or branched chain 
alkyl radicals having in the range of l to 4 carbon atoms. 
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The term “alkyl” refers to straight or branched chain alkyl 
radicals having 1 to 19 carbon atoms, and “substituted alkyl” 
refers to alkyl radicals further bearing one or more substitu 
ents including, but not limited to, hydroxy, alkoxy (of a loWer 
alkyl group), mercapto (of a loWer alkyl group), aryl, hetero 
cyclic, halogen, tri?uoromethyl, cyano, nitro, amino, car 
boxyl, carbamate, sulfonyl, and sulfonamide. 
The term “cycloalkyl” refers to cyclic ring-containing moi 
eties containing 3 to 8 carbon atoms, and “substituted 
cycloalkyl” refers to cycloalkyl moieties further bearing one 
or more substituents as set forth above. 
The term “alkenyl” refers to straight or branched chain 
hydrocarbyl groups having at least one carbon-carbon double 
bond and having 2 to 19 carbon atoms, and “substituted 
alkenyl” refers to alkenyl groups further bearing one or more 
substituents as set forth above. 
The term “alkynyl” refers to straight or branched chain 
hydrocarbyl moieties having at least one carbon-carbon triple 
bond and having 2 to 19 carbon atoms, and “substituted 
alkynyl” refers to alkynyl moieties further bearing one or 
more substituents as set forth above. 
The term “aryl” refers to aromatic groups having 6 to 24 
carbon atoms, and “substituted aryl” refers to aryl groups 
further bearing one or more substituents as set forth above. 
The term “alkylaryl” refers to alkyl-substituted aryl 
groups, and “substituted alkylaryl” refers to alkylaryl groups 
further bearing one or more substituents as set forth above. 
The term “arylalkyl” refers to aryl-substituted alkyl 
groups, and “substituted arylalkyl” refers to arylalkyl groups 
further bearing one or more substituents as set forth above. 
The term “arylalkenyl” refers to aryl-substituted alkenyl 
groups, and “substituted arylalkenyl” refers to arylalkenyl 
groups further bearing one or more substituents as set forth 
above. 
The term “arylalkynyl” refers to aryl-substituted alkynyl 
groups, and “substituted arylalkynyl” refers to arylalkynyl 
groups further bearing one or more substituents as set forth 
above. 
The term “heterocyclic” refers to cyclic moieties contain 
ing one or more heteroatoms as part of the ring structure and 
having 3 to 24 carbon atoms, and “substituted heterocyclic” 
refers to heterocyclic moieties further bearing one or more 
substituents as set forth above. 
The term “acyl” refers to alkyl-carbonyl groups, and “sub 
stituted acyl” refers to acyl groups further bearing one or 
more substituents as set forth above. 
The term “halogen” refers to ?uoride, chloride, bromide or 
iodide groups. 
It is understood that in all substituted groups de?ned above, 
polymers arrived at by de?ning sub stituents With further sub 
stituents to themselves (e. g. substituted aryl having a substi 
tuted aryl group as a substituent Which is itself substituted 
With a substituted aryl group, etc.) are not intended for inclu 
sion herein. In such cases, the maximum number of such 
substituents is three. That is to say that each of the above 
de?nitions is constrained by a limitation that, for example, 
substituted aryl groups are limited to -substituted aryl-(sub 
stituted aryl)-sub stituted aryl. 
Compounds of the present invention are tris-quaternary 
ammonium salts corresponding to Formula (I): 
(1) 
to // 
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The three side chains attached to the phenyl ring may be 
connected to the 1, 2, and3 positions; the 1, 2, and 4 positions; 
or the 1, 3 and 5 positions of the phenyl ring. 
The values for m1, m2 and m3 are each independently 0, 1, 
2, 3, 4 or 5. 
The values for n1, n2, and n3 are each independently 1, 2, 
3, 4 or 5. 
X19, X29, and X39 are each independently an organic or 
inorganic anion. 
Ll, L2 and L3 are each independently chosen from the 
group consisting of 4CH24CH2i, cis 4CH:CHi, 
trans 4CH:CHi, 4CECi, iCHZiSi, 
iSiCHZi, iseiCHzi, %H2iSei, %H2A)i, 
iO%H2i, iCHziNHi, iNH%H2i, %H2i 
NRi Where R is a branched or straight chain alkyl group of 
one to four carbons, iNR4CH2i Where R is a branched or 
straight chain alkyl group of one to four carbons, 
iCH:Ni, iN:CHi, and iN:Ni. 
R1, R2, and R3 are each independently ?ve or six membered 
nitrogen containing rings as shoWn in formulas (HA) and 
(11B). 
(HA) 
(HE) 
A1 is carbon or nitrogen, provided that WhenAl joins a ring 
atom With an unsaturated bond or is a nitrogen, R9 is absent, 
and When A1 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R4 and R9 are absent. 
A2 is carbon or nitrogen, provided that When A2 joins a ring 
atom With an unsaturated bond or is a nitrogen, R10 is absent, 
and When A2 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R5 and R10 are absent. 
A3 is carbon or nitrogen, provided that When A3 joins a ring 
atom With an unsaturated bond or is a nitrogen, R1 l is absent, 
and When A3 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R6 and R11 are absent. 
A4 is carbon or nitrogen, provided that When A4 j oins a ring 
atom With an unsaturated bond or is a nitrogen, R12 is absent, 
and When A4 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R7 and R12 are absent. 
A5 is carbon or nitrogen, provided that When A5 joins a ring 
atom With an unsaturated bond or is a nitrogen, R13 is absent, 
and When A5 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R8 and R13 are absent. 
A6 is carbon or nitrogen, provided that When A6 joins a ring 
atom With an unsaturated bond or is a nitrogen, R19 is absent, 
and When A6 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R15 and R19 are absent. 
A7 is carbon or nitrogen, provided that When A7 joins a ring 
atom With an unsaturated bond or is a nitrogen, R20 is absent, 
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8 
and When A7 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R16 and R20 are absent. 
A8 is carbon or nitrogen, provided that WhenA8 joins a ring 
atom With an unsaturated bond or is a nitrogen, R21 is absent, 
and When A8 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R17 and R21 are absent. 
A9 is carbon or nitrogen, provided that WhenA9 joins a ring 
atom With an unsaturated bond or is a nitrogen, R22 is absent, 
and When A9 joins a ring atom With an unsaturated bond and 
is a nitrogen, both R18 and R22 are absent. 
R14 or R23 is absent When any of the bonds to the ammo 
nium nitrogen is unsaturated, and R14 or R23 is a straight chain 
or branched alkyl group of four carbons or feWer When all of 
the bonds to the ammonium nitrogen are saturated. 
R4’ R5’ R6’ R7’ R8’ R9’ R10’ R11’ R12’ and R13 or R15’ R16, 
R17, R18, R19, R20, R21, and R22, When present, are each 
independently selected from hydrogen, alkyl, substituted 
alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, 
alkylaryl, substituted alkylaryl, arylalkyl, substituted aryla 
lkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substi 
tuted arylalkynyl, heterocyclic, substituted heterocyclic, 
halo, cyano, nitro, SOYl, SOZYI, SO2OYl or SO2NHY1, 
where Y1 is selected from hydrogen, loWer alkyl, alkenyl, 
alkynyl or aryl, and WhereYl is not hydrogen in SOYl and if 
Y1 is alkenyl or alkynyl, the site of unsaturation is not conju 
gated With a heteroatom; COY2, Where Y2 is selected from 
hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted 
cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, sub 
stituted alkynyl, aryl, substituted aryl, alkylaryl, substituted 
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substi 
tuted arylalkenyl, arylalkynyl, substituted arylalkynyl, het 
erocyclic, or substituted heterocyclic, and Where if Y2 com 
prises alkenyl or alkynyl, the site of unsaturation is not 
conjugated With the carbonyl group; 0Y3, Where Y3 is 
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi 
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocy 
clic, or substituted heterocyclic, Where if Y3 comprises alk 
enyl or alkynyl, the site of unsaturation is not conjugated With 
the oxygen; NY4Y5 , Where Y4 and Y5 are each independently 
selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, alkylaryl, substi 
tuted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, 
acyl, substituted acyl, alkylsulfonyl, arylsulfonyl, heterocy 
clic, or substituted heterocyclic, Where if Y4 orY5 comprises 
alkenyl or alkynyl, the site of unsaturation is not conjugated 
With the nitrogen; SY6, Where Y6 is selected from hydrogen, 
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, 
aryl, substituted aryl, alkylaryl, substituted alkylaryl, aryla 
lkyl, substituted arylalkyl, arylalkenyl, substituted arylalk 
enyl, arylalkynyl, substituted arylalkynyl, heterocyclic, or 
substituted heterocyclic, and Where ifY6 comprises alkenyl or 
alkynyl, the site of unsaturation is not conjugated With the 
sulfur; or R4 and R5 together With A1 and A2, or R5 and R6 
together With A2 and A3, or R15 and R1 6 together With A6 and 
A7, or R16 and R17 together With A7 and A8 independently 
form a three to eight member cycloalkane, substituted 
cycloalkane, cycloalkene, substituted cycloalkene, aryl, sub 
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stituted aryl, heterocycle With one to three hetero atoms in the 
ring, or substituted heterocycle With one to three hetero atoms 
in the ring. 
For example, R1, R2, and R3 include pyrrole, pyrrolidine, 
pyraZole, imidaZole, 1,2,3-triaZole, 1,2,4-triaZole, pyridine, 
piperidine, quinoline, tetrahydroquinoline, isoquinoline, tet 
rahydroisoquinoline, pyraZine, piperaZine, pyridaZine, and 
triaZine. 
As another example, R4, R5, R6, R7, R8, R9, R10, R11, R12, 
R13’ R14’ R15’ R16, R17’ R18, R19’ R20’ R21’ and R22’ include 
hydrogen, methyl, ethyl, propyl, butyl, tri?uoromethyl, pyr 
rolidine, N-alkyl pyrrolidine (for example Where the alkyl 
chain is methyl, ethyl or propyl), unsaturated pyrrolidine, 
unsaturated N-alkyl pyrrolidine (for example Where the alkyl 
chain is methyl, ethyl or propyl), aZiridine, N-methyl aZiri 
dine, aZetidine, N-methyl aZetidine, unsaturated aZetidine, 
unsaturated N-methyl aZetidine, piperidine, N-methyl piperi 
dine, unsaturated piperidine, unsaturated N-methyl piperi 
dine, aZepane, N-methyl aZepane, unsaturated aZepane, 
unsaturated N-methyl aZepane, aZocane, N-methyl aZocane, 
unsaturated aZocane, unsaturated N-methyl aZocane, 1-aZa 
bicyclo[3.2.1]octane, 1-aZa-bicyclo[2.2.1]heptane, 8-me 
thyl-8-aZa-bicyclo[3.2.1]octane, 1-aZa-tricyclo[3.3.1.13’7] 
decane, methyl cycloalkyl, methyl substituted cycloalkyl, 
methyl pyrrolidine, methyl N-alkyl pyrrolidine (for example 
Where the alkyl chain is methyl, ethyl or propyl), methyl 
unsaturated pyrrolidine, methyl unsaturated N-alkyl pyrroli 
dine (for example Where the alkyl chain is methyl, ethyl or 
propyl), methyl aZiridine, methyl N-methyl aZiridine, methyl 
aZetidine, methyl N-methyl aZetidine, methyl unsaturated 
aZetidine, methyl unsaturated N-methyl aZetidine, methyl 
piperidine, methyl N-methyl piperidine, methyl unsaturated 
piperidine, methyl unsaturated N-methyl piperidine, methyl 
aZepane, methyl N-methyl aZepane, methyl unsaturated 
aZepane, methyl unsaturated N-methyl aZepane, methyl aZo 
cane, methyl N-methyl aZocane, methyl unsaturated aZocane, 
methyl unsaturated N-methyl aZocane, methyl-1 -aZa-bicyclo 
[3.2.1]octane, methyl-1-aZa-bicyclo[2.2.1]heptane, 8-me 
thyl-8-aZa-bicyclo[3.2.1]octane, and methyl-1-aZa-tricyclo 
[3.3.1.13’7]decane. 
As a further example, When R4 and R5 together WithAl and 
A2, or R5 and R6 together With A2 and A3, or R15 and R16 
together With A6 and A7, or R1 6 and R17 together With A7 and 
A8 independently form a three to eight-membered ring, that 
ring may be a heterocycle containing up to three hetero atoms 
(for example nitrogen, oxygen or sulfur) in the ring, and 
further may be substituted With one or more substituents. For 
example, possible rings include benZene, pyridine, pyran, 
indene, isoindene, benZofuran, isobenZofuran, benZo [b] 
thiophene, benZo[c]thiophene, indole, indolenine, isoindole, 
cyclopental[b]pyridine, pyrano[3,4-b]pyrrole, indaZole, 
indoxaZine, benZoxaZole, anthranil naphthalene, tetralin, 
decalin, chromene, coumarin, chroman-4-one, isocoumarin, 
isochromen-3-one, quinoline, isoquinoline, cinnoline, 
quinaZoline, naphthyrdine, pyrido[3,4-b]-pyridine, pyridol 
[3,2-b]pyridine, pyrido[4,3,-b]-pyridine, benZoxaZine, 
anthracene, phenanthrene, phenalene, ?uorene, caraZole, 
xanthene, acnidine, octahydro-[1]pyridine, 1-methyloctahy 
dro-[1]pyridine, octahydroindole, l-methyloctahydroindole, 
octahydro-cyclopenta[b]pyrrole, 1-methyloctahydro-cyclo 
penta[b]pyrrole, decahydroquinoline, and 1-methyldecahyd 
roquinoline. 
X19, X29, and X39, for example, include F‘, Cl‘, Br‘, I‘, 
N02“, HSO4_, SO4_, HPO4_, PO42“, methanesulfonate, tri 
?uromethane sulfate, p-toluenesulfonate, benZenesulfonate, 
salicylate, proprionate, ascorbate, aspartate, fumarate, galac 
tarate, maleate, citrate, glutamate, glycolate, lactate, malate, 
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maleate, tartrate, oxalate, succinate, or similar pharmaceuti 
cally acceptable organic acid addition salts, including the 
pharmaceutically acceptable salts listed in the Journal of 
Pharmaceutical Sciences Volume 66, page 2, 1977, Which are 
hereby incorporated by reference. The above salt forms may 
be in some cases hydrates or solvates With alcohols and other 
solvents. 
In a compound of Formula (I), preferably the phenyl ring is 
substituted at the 1, 3 and 5 positions. 
In a compound of Formula (I), preferably A1, A2, A3, A4, 
and A5 are carbon. 
In a compound of Formula (I), preferably R1, R2, and R3 
are substituted, six-membered, aromatic rings. More prefer 
ably, R1, R2, and R3 are substituted pyridinium rings. 
In a compound of Formula (I), preferably R4 is hydrogen, 
alkyl, or forms an aryl ring With A1, A2 and R5 . More prefer 
ably, R4 is hydrogen, methyl or forms a phenyl group withAl, 
A2 and R5 . 
In a compound of Formula (I), preferably R5 is hydrogen, 
alkyl, phenyl, 1-methyl-2-pyrrolidinyl, forms a six-mem 
bered ring With A1, A2 and R4, or forms an aryl ring With A2, 
A3 and R6. More preferably, R5 is hydrogen, methyl, butyl, 
phenyl, 1-methyl-2-pyrrolidinyl, forms a phenyl group With 
A1, A2 and R4, or forms a phenyl group With A2, A3 and R6. 
In a compound of Formula (I), preferably R6 is hydrogen, 
alkyl, or forms an aryl ring With A2, A3 and R5 . More prefer 
ably, R6 is hydrogen, methyl or forms a phenyl group WithA2, 
A3 and R5 . 
In a compound of Formula (I), preferably R7 is hydrogen or 
alkyl. More preferably, R7 is hydrogen or methyl. 
In a compound of Formula (I), preferably R5 is hydrogen. 
In a compound of Formula (I), preferably m:0. 
In a compound of Formula (I), preferably n:3. 
In a compound of Formula (I), preferably L1, L2 and L3 are 
%H2%H2i or *CECi. 
In a compound of Formula (I), preferably X19, X29, and 
X39 are halogens. More preferably, X19, X29, and X39 are 
bromide. 
In one embodiment, the compound of Formula (I) is 
de?ned Wherein the phenyl ring is 1,3,5 substituted; Wherein 
m:0; Wherein n:3; Wherein L is iCHZCHZi or 4CECi; 
Wherein R1, R2, and R3 are pyridinium rings; Wherein R4 is 
hydrogen, methyl or forms a phenyl group W1IhAl,A2 and R5 ; 
Wherein R5 is hydrogen, methyl, phenyl, butyl, 1-methyl-2 
pyrrolidinyl, forms a phenyl group With A1, A2 and R4, or 
forms a phenyl group With A2, A3 and R6; Wherein R6 is 
hydrogen, methyl or forms a phenyl group WithA2, A3 and R5 ; 
and Wherein X1, X2, and X3 are Br. 
In another embodiment, the compound of Formula (I) is 
de?ned Wherein the phenyl ring is 1,3,5 substituted; Wherein 
m:0; Wherein n:3; Wherein L is iCHZCHZi; Wherein R1, 
R2, and R3 are pyridinium rings; Wherein R4 is hydrogen, 
methyl or forms a phenyl group With A1, A2 and R5; Wherein 
R5 is hydrogen, methyl, phenyl, butyl, 1-methyl-2-pyrrolidi 
nyl, forms a phenyl group With A1, A2 and R4, or forms a 
phenyl group With A2, A3 and R6; Wherein R6 is hydrogen, 
methyl or forms a phenyl group With A2, A3 and R5; and 
Wherein X1, X2, and X3 are Br. 
In another embodiment, the compound of Formula (I) is 
de?ned Wherein the phenyl ring is 1,3,5 substituted; Wherein 
m:0; Wherein n:3; Wherein L is 4CECi; Wherein R1, R2, 
and R3 are pyridinium rings; Wherein R4 is hydrogen, methyl 
or forms a phenyl group With A1, A2 and R5; Wherein R5 is 
hydrogen, methyl, phenyl, butyl, 1-methyl-2-pyrrolidinyl, 
forms a phenyl group With A1, A2 and R4, or forms a phenyl 
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group With A2, A3 and R6; wherein R6 is hydrogen, methyl or 
forms a phenyl group WithA2, A3 and R5 ; and Wherein X1, X2, 
and X3 are Br. 
Exemplary compounds for this application are presented in 
Table 1. 
1 2 
(3 -phenyl -pyridinium) -p entyl] -benZene tribromide; 1 ,3 ,5 - 
tris-{ 5 -[3 -(1-methyl-2-S-pyrrolidinyl)pyridinium]-pentyl} 
benzene tribromide; 1,3,5 -tris- [5 -(1-quinolinium)-pentyl] 
benzene tribromide; 1,3,5 -tris-[5 -(2-isoquinolinium) 
pentyl] -benZene tribromide; 1,3, 5-tris-[5-(3 ,5 -lutidinium) 
TAB LE 1 
I N@ L L NI 
R5 / W W(9 / R5 
R4 R4 
9 
3 Br 
L 
R4 N (9 | \ 
R5 / R7 
R6 
ID # R4 R5 R6 R7 L 
GZ55OA hydrogen methyl hydrogen hydrogen 4CECi 
GZ55OB hydrogen phenyl hydrogen hydrogen 4CECi 
GZ551A hydrogen butyl hydrogen hydrogen 4CECi 
GZ551B hydrogen 1-methyl- hydrogen hydrogen 4CECi 
2-pyrrolidinyl 
GZ552A phenyl phenyl hydrogen hydrogen 4C:Ci 
With R5 With R4 
GZ552B hydrogen phenyl phenyl hydrogen 4C:Ci 
With R6 With R5 
GZ553A hydrogen methyl hydrogen methyl 4C:Ci 
GZ553B hydrogen methyl methyl hydrogen 4CECi 
GZ554A methyl hydrogen hydrogen hydrogen 4CECi 
GZ5 54B hydrogen hydrogen methyl hydrogen 4CECi 
GZ555A hydrogen methyl hydrogen hydrogen 4CH2CH2i 
GZ555B methyl hydrogen hydrogen hydrogen 4CH2CH2i 
GZ555C hydrogen hydrogen methyl hydrogen 4CH2CH2i 
GZ55 6A phenyl phenyl hydrogen hydrogen 4CH2CH2i 
With R5 With R4 
GZ556B hydrogen phenyl phenyl hydrogen 4CH2CH2i 
With R6 With R5 
GZ557A hydrogen methyl hydrogen methyl 4CH2CH2i 
GZ557B hydrogen methyl methyl hydrogen 4CH2CH2i 
GZ55 8A hydrogen phenyl hydrogen hydrogen 4CH2CH2i 
GZ558B hydrogen butyl hydrogen hydrogen 4CH2CH2i 
GZ558C hydrogen 1-methyl-2- hydrogen hydrogen 4CH2CH2i 
pyrroli dinyl 
Exemplary compounds of the present invention include: 50 pentyl] -benZene tribromide; and 1,3,5-tris-[5-(3,4 
1,3 ,5 -tris- [5 -(2-picolinium)-pent-1-ynyl]-benZene tribro 
mide; 1,3,5 -tris- [5 -(3 -picolinium)-pent-1-ynyl]-benZene tri 
bromide; 1,3,5 -tris- [5 -(4-picolinium)-pent-1-ynyl]-benZene 
tribromide; 1,3,5 -tris- [5 -(3 -butyl-pyridinium)-pent-1-ynyl] 
benZene tribromide; 1,3,5 -tris- [5 -(3 -phenyl-pyridinium) 
pent-1-ynyl]-benZene tribromide; 1,3,5 -tris- { 5 -[3 -(1-me 
thyl-2- S -pyrrolidinyl)pyridinium] -p ent-1 -ynyl} -benZene 
tribromide; 1,3,5 -tris- [5 -(1-quinolinium)-pent-1-ynyl]-ben 
Zene tribromide; 1,3,5 -tris- [5 -(2-isoquinolinium)-pent-1 
ynyl] -benZene tribromide; 1,3, 5-tris-[5-(3 ,5 -lutidinium) 
pent-1-ynyl]-benZene tribromide; 1,3,5-tris-[5-(3,4 
lutidinium) -pent- 1 -ynyl] -benZene tribromide; 1 ,3 ,5 -tris- [5 - 
(2-picolinium)-pentyl] -benZene tribromide; 1,3, 5-tris-[5-(3 - 
picolinium) -pentyl] -benZene tribromide; 1,3, 5-tris-[5-(4 
picolinium) -pentyl] -benZene tribromide; 1,3, 5-tris-[5-(3 - 
butyl-pyridinium)-pentyl] -benZene tribromide; 1,3,5 -tris- [5 - 
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lutidinium)-pentyl] -benZene tribromide. 
The compounds of the present invention may contain one 
or more stereocenters. The invention includes all possible 
diastereomers and all enantiomeric forms as Well as racemic 
mixtures. The compounds can be separated into substantially 
optically pure compounds. 
The compounds of the invention are nicotinic acetylcho 
line receptor agents. Thus, they may augment or inhibit [3 H] 
nicotine binding, [3H]MLA binding, evoke or inhibit neu 
rotransmitter release, and/or evoke or inhibit the ?ux of ions 
through the nicotinic receptor. Moreover, the compounds of 
the invention may act either at presynaptic sites or postsyn 
aptic sites, for example, at a postsynaptic acetylcholine recep 
tor containing an (X7 subunit. When acting at a postsynaptic 
site, neurotransmitter release per se is not altered. Rather, the 
compounds of the invention may act by interacting With a 
postsynaptic acetylcholine receptor to change the membrane 
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potential of the cell, thereby increasing or decreasing the 
likelihood of ?ring an action potential. Alternatively, interac 
tion of a compound of the invention With a postsynaptic 
acetylcholine receptor may result in the alteration of one or 
more second messenger systems Within the cell so as to 
decrease or increase the nicotinic cholinergic response. 
In one embodiment, the present invention relates to a 
method for selectively modulating the function of a nicotinic 
acetylcholine receptor comprising administering to a mam 
malian subject in need thereof a therapeutically effective 
amount of a compound of Formula (I). In such a method, the 
compound of Formula (I) may selectively bind to one or more 
subtypes of nicotinic acetylcholine receptor. The compound 
of Formula (I) may act as an agonist or partial agonist of 
nicotinic acetylcholine receptor function. Hence the com 
pound of Formula (I) may increase or prolong the release of a 
neurotransmitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi 
nephrine, serotonin, gamma-aminobutyric acid, or glutamate. 
Alternatively, the compound of Formula (I) may act as an 
antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. In this regard, the compound of For 
mula (I) may act by decreasing stimulant-evoked neurotrans 
mitter release. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutyric 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act by interacting With a postsynaptic acetylcholine 
receptor to change the membrane potential of the cell thereby 
increasing or decreasing the likelihood of ?ring an action 
potential, or to alter one or more second messenger systems 
Within the cell so as to decrease or increase the nicotinic 
cholinergic response. 
In another embodiment, the present invention is directed to 
a method for preventing and/or treating a central nervous 
system associated disorder comprising administering to a 
mammalian subject in need thereof a therapeutically effective 
amount of a compound of Formula (I). In such a method, the 
compound of Formula (I) may selectively bind to one or more 
subtypes of nicotinic acetylcholine receptor. The compound 
of Formula (I) may act as an against or partial agonist of 
nicotinic acetylcholine receptor function. Hence the com 
pound of Formula (I) may increase or prolong the release of a 
neurotransmitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi 
nephrine, serotonin, gamma-aminobutyric acid, or glutamate. 
Alternatively, the compound of Formula (I) may act as an 
antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. In this regard, the compound of For 
mula (I) may act by decreasing stimulant-evoked neurotrans 
mitter release. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutyric 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act by interacting With a postsynaptic acetylcholine 
receptor to change the membrane potential of the cell thereby 
increasing or decreasing the likelihood of ?ring an action 
potential, or to alter one or more second messenger systems 
Within the cell so as to decrease or increase the nicotinic 
cholinergic response. 
Central nervous system disorders Which may be treated 
according to the method of the present invention include 
AlZheimer’s disease, dementia, cognitive dysfunctions (in 
cluding disorders of attention, focus and concentration), 
attention de?cit disorders, affective disorders, extrapyrami 
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dal motor function disorders, Parkinson’s disease, progres 
sive supramolecular palsy, Huntington’s disease, Gilles de la 
Tourette syndrome, tardive dyskinesia, neuroendocrine dis 
orders, dysregulation of food intake, disorders of nociception, 
pain, mood and emotional disorders, depression, panic anxi 
ety, psychosis, schiZophrenia, or epilepsy. 
In yet another embodiment, the present invention is 
directed to a method for preventing and/ or treating sub stance 
use and/or abuse comprising administering to a mammalian 
subject in need thereof a therapeutically effective amount of a 
compound of Formula (I). In such a method, the compound of 
Formula (I) may selectively bind to one or more subtypes of 
nicotinic acetylcholine receptor. The compound of Formula 
(I) may act as an agonist or partial agonist of nicotinic ace 
tylcholine receptor function. Hence the compound of For 
mula (I) may increase or prolong the release of a neurotrans 
mitter from a central nervous system tissue. The 
neurotransmitter affected may include dopamine, norepi 
nephrine, serotonin, gamma-aminobutyric acid, or glutamate. 
Alternatively, the compound of Formula (I) may act as an 
antagonist of nicotinic acetylcholine receptor function. 
Hence the compound of Formula (I) may decrease the extent 
or duration of the release of a neurotransmitter from a central 
nervous system tissue. In this regard, the compound of For 
mula (I) may act by decreasing stimulant-evoked neurotrans 
mitter release. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutyric 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act by interacting With a postsynaptic acetylcholine 
receptor to change the membrane potential of the cell thereby 
increasing or decreasing the likelihood of ?ring an action 
potential, or to alter one or more second messenger systems 
Within the cell so as to decrease or increase the nicotinic 
cholinergic response. 
The conditions of substance use and/or abuse treated 
according to the method of the present invention include 
nicotine abuse (including use in smoking cessation therapy), 
nicotine intoxication, amphetamine abuse, methamphet 
amine abuse, MDMA (methylenedioxymethamphetamine) 
abuse, methylphenidate abuse, cocaine abuse, or alcohol 
abuse. 
In another embodiment, the present invention is directed to 
a method for preventing and/ or treating gastrointestinal tract 
disorders comprising administering to a mammalian subject 
in need thereof a therapeutically effective amount of a com 
pound of Formula (I). In such a method, the compound of 
Formula (I) may selectively bind to one or more subtypes of 
nicotinic acetylcholine receptor. The compound of Formula 
(I) may act as an agonist or partial agonist of nicotinic ace 
tylcholine receptor function. Hence the compound of For 
mula (I) may increase or prolong the release of a neurotrans 
mitter from a central nervous system tissue, or may increase 
or prolong the release of a neurotransmitter from a peripheral 
nervous system tissue, or may act directly on a gastrointesti 
nal tract tissue. The neurotransmitter affected may include 
dopamine, norepinephrine, serotonin, gamma-aminobutyric 
acid, or glutamate. Alternatively, the compound of Formula 
(I) may act as an antagonist of nicotinic acetylcholine recep 
tor function. Hence the compound of Formula (I) may 
decrease the extent or duration of the release of a neurotrans 
mitter from a central nervous system tissue, or may decrease 
the extent or duration of the release of a neurotransmitter from 
a peripheral nervous system tissue, or may act directly on a 
gastrointestinal tract tissue. In this regard, the compound of 
Formula (I) may act by decreasing stimulant-evoked neu 
rotransmitter release. The neurotransmitter affected may 
include dopamine, norepinephrine, serotonin, gamma-ami 
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nobutyric acid, or glutamate. Alternatively, the compound of 
Formula (I) may act by interacting With a postsynaptic ace 
tylcholine receptor to change the membrane potential of the 
cell thereby increasing or decreasing the likelihood of ?ring 
an action potential, or to alter one or more second messenger 
systems Within the cell so as to decrease or increase the 
nicotinic cholinergic response. 
Gastrointestinal disorders Which may be treated according 
to the method of the present invention include irritable boWel 
syndrome, colitis, diarrhea, constipation, gastric acid secre 
tion or ulcers. 
The compounds of the present invention can be delivered 
directly or in pharmaceutical compositions along With suit 
able carriers or excipients, as is Well knoWn in the art. For 
example, a pharmaceutical composition of the invention may 
include a conventional additive, such as a stabilizer, buffer, 
salt, preservative, ?ller, ?avor enhancer and the like, as knoWn 
to those skilled in the art. Exemplary buffers include phos 
phates, carbonates, citrates and the like. Exemplary preserva 
tives include EDTA, EGTA, BHA, BHT and the like. 
An effective amount of such agents can readily be deter 
mined by routine experimentation, as can the most effective 
and convenient route of administration and the most appro 
priate formulation. Various formulations and drug delivery 
systems are available in the art. See, e. g., Gennaro, A. R., ed. 
(1995) Remington’s Pharmaceutical Sciences. 
Suitable routes of administration may, for example, 
include oral, rectal, transmucosal, nasal, or intestinal admin 
istration and parenteral delivery, including intramuscular, 
subcutaneous, intramedullary injections, as Well as intrathe 
cal, direct intraventricular, intravenous, intraperitoneal, intra 
nasal, or intraocular injections. In addition, the agent or com 
position thereof may be administered sublingually or via a 
spray. The agent or composition thereof may be administered 
in a local rather than a systemic manner. For example, a 
suitable agent can be delivered via injection or in a targeted 
drug delivery system, such as a depot or sustained release 
formulation. 
The pharmaceutical compositions of the present invention 
may be manufactured by any of the methods Well-knoWn in 
the art, such as by conventional mixing, dissolving, granulat 
ing, dragee-making, levigating, emulsifying, encapsulating, 
entrapping, or lyophilizing processes. As noted above, the 
compositions of the present invention can include one or 
more physiologically acceptable carriers such as excipients 
and auxiliaries that facilitate processing of active molecules 
into preparations for pharmaceutical use. 
Proper formulation is dependent upon the route of admin 
istration chosen. For injection, for example, the composition 
may be formulated in aqueous solutions, preferably in physi 
ologically compatible buffers such as Hanks’ solution, Ring 
er’ s solution, or physiological saline buffer. For transmucosal 
or nasal administration, penetrants appropriate to the barrier 
to be permeated are used in the formulation. Such penetrants 
are generally knoWn in the art. In a preferred embodiment of 
the present invention, the present compounds are prepared in 
a formulation intended for oral administration. For oral 
administration, the compounds can be formulated readily by 
combining the active compounds With pharmaceutically 
acceptable carriers Well knoWn in the art. Such carriers enable 
the compounds of the invention to be formulated as tablets, 
pills, dragees, capsules, liquids, gels, syrups, slurries, suspen 
sions and the like, for oral ingestion by a subject. The com 
pounds may also be formulated in rectal compositions such as 
suppositories or retention enemas, e.g., containing conven 
tional suppository bases such as cocoa butter or other glyc 
erides. 
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Pharmaceutical preparations for oral use canbe obtained as 
solid excipients, optionally grinding a resulting mixture, and 
processing the mixture of granules, after adding suitable aux 
iliaries, if desired, to obtain tablets or dragee cores. Suitable 
excipients are, in particular, ?llers such as sugars, including 
lactose, sucrose, mannitol, or sorbitol; cellulose preparations 
such as, for example, maize starch, Wheat starch, rice starch, 
potato starch, gelatin, gum tragacanth, methyl cellulose, 
hydroxypropylmethyl-cellulose, sodium carboxymethylcel 
lulose, and/or polyvinylpyrrolidone (PVP). If desired, disin 
tegrating agents may be added, such as the cross-linked poly 
vinyl pyrrolidone, agar, or alginic acid or a salt thereof such as 
sodium alginate. Also, Wetting agents such as sodium dodecyl 
sulfate may be included. 
Dragee cores are provided With suitable coatings. For this 
purpose, concentrated sugar solutions may be used, Which 
may optionally contain gum arabic, talc, polyvinyl pyrroli 
done, carbopol gel, polyethylene glycol, and/or titanium 
dioxide, lacquer solutions, and suitable organic solvents or 
solvent mixtures. Dyestuffs or pigments may be added to the 
tablets or dragee coatings for identi?cation or to characterize 
different combinations of active compound doses. 
Pharmaceutical preparations for oral administration 
include push-?t capsules made of gelatin, as Well as soft, 
sealed capsules made of gelatin and a plasticizer, such as 
glycerol or sorbitol. The push-?t capsules can contain the 
active ingredients in admixture With ?ller such as lactose, 
binders such as starches, and/or lubricants such as talc or 
magnesium stearate and, optionally, stabilizers. In soft cap 
sules, the active compounds may be dissolved or suspended in 
suitable liquids, such as fatty oils, liquid paraf?n, or liquid 
polyethylene glycols. In addition, stabilizers may be added. 
All formulations for oral administration should be in dosages 
suitable for such administration. 
In one embodiment, the compounds of the present inven 
tion can be administered transdermally, such as through a skin 
patch, or topically. In one aspect, the transdermal or topical 
formulations of the present invention can additionally com 
prise one or multiple penetration enhancers or other effectors, 
including agents that enhance migration of the delivered com 
pound. Transdermal or topical administration could be pre 
ferred, for example, in situations in Which location speci?c 
delivery is desired. 
For administration by inhalation, the compounds for use 
according to the present invention are conveniently delivered 
in the form of an aerosol spray presentation from pressurized 
packs or a nebulizer, With the use of a suitable propellant, e. g., 
dichlorodi?uoromethane, trichloro?uoromethane, dichlo 
rotetra?uoroethane, carbon dioxide, or any other suitable gas. 
In the case of a pressurized aerosol, the appropriate dosage 
unit may be determined by providing a valve to deliver a 
metered amount. Capsules and cartridges of, for example, 
gelatin, for use in an inhaler or insuf?ator may be formulated. 
These typically contain a poWder mix of the compound and a 
suitable poWder base such as lactose or starch. 
Compositions formulated for parenteral administration by 
injection, e. g., by bolus injection or continuous infusion can 
be presented in unit dosage form, e.g., in ampoules or in 
multi-dose containers, With an added preservative. The com 
positions may take such forms as suspensions, solutions, or 
emulsions in oily or aqueous vehicles, and may contain for 
mulatory agents such as suspending, stabilizing and/or dis 
persing agents. Formulations for parenteral administration 
include aqueous solutions or other compositions in Water 
soluble form. 
Suspensions of the active compounds may also be prepared 
as appropriate oily injection suspensions. Suitable lipophilic 
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solvents or vehicles include fatty oils such as sesame oil and 
synthetic fatty acid esters, such as ethyl oleate or triglycer 
ides, or liposomes. Aqueous injection suspensions may con 
tain substances that increase the viscosity of the suspension, 
such as sodium carboxymethyl cellulose, sorbitol, or dextran. 
Optionally, the suspension may also contain suitable stabiliZ 
ers or agents that increase the solubility of the compounds to 
alloW for the preparation of highly concentrated solutions. 
Alternatively, the active ingredient may be in poWder form for 
constitution With a suitable vehicle, e.g., sterile pyrogen-free 
Water, before use. 
As mentioned above, the compositions of the present 
invention may also be formulated as a depot preparation. 
Such long acting formulations may be administered by 
implantation (for example, subcutaneously or intramuscu 
larly) or by intramuscular injection. Thus, for example, the 
present compounds may be formulated With suitable poly 
meric or hydrophobic materials (for example as an emulsion 
in an acceptable oil) or ion exchange resins, or as sparingly 
soluble derivatives, for example, as a sparingly soluble salt. 
Suitable carriers for the hydrophobic molecules of the 
invention are Well known in the art and include co-solvent 
systems comprising, for example, benZyl alcohol, a nonpolar 
surfactant, a Water-miscible organic polymer, and an aqueous 
phase. The co-solvent system may be the VPD co-solvent 
system. VPD is a solution of 3% W/v benZyl alcohol, 8% W/v 
of the nonpolar surfactant polysorbate 80, and 65% W/v poly 
ethylene glycol 300, made up to volume in absolute ethanol. 
The VPD co-solvent system (V PD15W) consists of VPD 
diluted 1:1 With a 5% dextrose in Water solution. This co 
solvent system is effective in dissolving hydrophobic com 
pounds and produces loW toxicity upon systemic administra 
tion. Naturally, the proportions of a co-solvent system may be 
varied considerably Without destroying its solubility and tox 
icity characteristics. Furthermore, the identity of the co-sol 
vent components may be varied. For example, other loW 
toxicity nonpolar surfactants may be used instead of 
polysorbate 80, the fraction siZe of polyethylene glycol may 
be varied, other biocompatible polymers may replace poly 
ethylene glycol, e. g., polyvinyl pyrrolidone, and other sugars 
or polysaccharides may substitute for dextrose. 
Alternatively, other delivery systems for hydrophobic mol 
ecules may be employed. Liposomes and emulsions are Well 
knoWn examples of delivery vehicles or carriers for hydro 
phobic drugs. Liposomal delivery systems are discussed 
above in the context of gene-delivery systems. Certain 
organic solvents such as dimethylsulfoxide also may be 
employed, although usually at the cost of greater toxicity. 
Additionally, the compounds may be delivered using sus 
tained-release systems, such as semi-permeable matrices of 
solid hydrophobic polymers containing the effective amount 
of the composition to be administered. Various sustained 
release materials are established and available to those of skill 
in the art. Sustained-release capsules may, depending on their 
chemical nature, release the compounds for a feW Weeks up to 
over 100 days. Depending on the chemical nature and the 
biological stability of the therapeutic reagent, additional 
strategies for stabiliZation may be employed. 
For any composition used in the present methods of treat 
ment, a therapeutically effective dose can be estimated ini 
tially using a variety of techniques Well knoWn in the art. For 
example, in a cell culture assay, a dose can be formulated in 
animal models to achieve a circulating concentration range 
that includes the lC5O as determined in cell culture. Dosage 
ranges appropriate for human subjects can be determined, for 
example, using data obtained from cell culture assays and 
other animal studies. 
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A therapeutically effective dose of an agent refers to that 
amount of the agent that results in amelioration of symptoms 
or a prolongation of survival in a subject. Toxicity and thera 
peutic e?icacy of such molecules can be determined by stan 
dard pharmaceutical procedures in cell cultures or experi 
mental animals, e. g., by determining the LD5O (the dose lethal 
to 50% of the population) and the ED5O (the dose therapeuti 
cally effective in 50% of the population). The dose ratio of 
toxic to therapeutic effects is the therapeutic index, Which can 
be expressed as the ratio LDSO/EDSO. Agents that exhibit high 
therapeutic indices are preferred. 
Dosages preferably fall Within a range of circulating con 
centrations that includes the ED5O With little or no toxicity. 
Dosages may vary Within this range depending upon the 
dosage form employed and the route of administration uti 
liZed. The exact formulation, route of administration, and 
dosage should be chosen, according to methods known in the 
art, in vieW of the speci?cs of a subject’s condition. 
The amount of agent or composition administered Will, of 
course, be dependent on a variety of factors, including the sex, 
age, and Weight of the subject being treated, the severity of the 
af?iction, the manner of administration, and the judgment of 
the prescribing physician. 
The present compositions may, if desired, be presented in a 
pack or dispenser device containing one or more unit dosage 
forms containing the active ingredient. Such a pack or device 
may, for example, comprise metal or plastic foil, such as a 
blister pack. The pack or dispenser device may be accompa 
nied by instructions for administration. Compositions com 
prising a compound of the invention formulated in a compat 
ible pharmaceutical carrier may also be prepared, placed in an 
appropriate container, and labeled for treatment of an indi 
cated condition. 
These and other embodiments of the present invention Will 
readily occur to those of ordinary skill in the art in vieW of the 
disclosure herein, and are speci?cally contemplated. 
EXAMPLES 
The invention is further understood by reference to the 
folloWing examples, Which are intended to be purely exem 
plary of the invention. The present invention is not limited in 
scope by the exempli?ed embodiments, Which are intended as 
illustrations of single aspects of the invention only. Any meth 
ods that are functionally equivalent are Within the scope of the 
invention. Various modi?cations of the invention in addition 
to those described herein Will become apparent to those 
skilled in the art from the foregoing description. Such modi 
?cations fall Within the scope of the appended claims. 
Example 1 
Preparation of 
1,3 , 5-tris-(5 -hydroxypent-1-ynyl)-benZene 
Br 
Br Br 
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-continued 
% HO OH % 
OH 
1,3,5-TribromobenZene (10 g, 31.76 mmol), 4-pentyn-1-ol 
(10.69 g, 127.06 mmol) and bis(triphenylphosphine)palla 
dium(ll) dichloride Were stirred in triethylamine under nitro 
gen for 5 minutes. Copper(l) iodide (92 mg, 0.48 mmol) Was 
added and the mixture Was stirred for 6 hours at 80° C. The 
mixture Was cooled to room temperature, ?ltered through a 
celite pad and rinsed With ethyl acetate. The combined ?ltrate 
Was evaporated to dryness under reduced pressure. The 
resulting residue Was puri?ed by column chromatography 
(CHCl3:MeOH 10:1) to afford 7.61 g of 1,3,5-tris-(5-hy 
droxy-1-pentynyl)-benZene. Yield: 74%. 1H NMR (300 
MHZ, CDCl3) 6 7.31 (3, 3h), 3.81 (t, 1:60 HZ, 6H), 2.52 (t, 
1:69 HZ, 6H), 1.85 (m, 6H); 13C NMR (75 MHZ, CDCl3) 6 
133.8, 124.2, 90.5, 80.0, 61.9, 31.5, 16.2 ppm. 
Example 2 
Preparation of 
1,3 ,5 -tris-(5 -bromopent-1-ynyl)-benZene 
HO % % 
Br 
Br 
1,3,5-tris-(5-hydroxy-1-pentynyl)-benZene (1.86 g, 5.73 
mmol) and carbon tetrabromide (7.41 g, 22.35 mmol) Were 
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dissolved in dry methylene chloride (40 mL) and cooled to 00 
C. Triphenyl phosphine (6.16 g, 23.47 mmol) Was added 
dropWide and the mixture Was stirred at 0° C. for 30 minutes. 
The mixture Was poured into hexanes (200 mL), ?ltered 
through a short silica gel column and Washed With ethyl 
acetate/hexanes (1/4). The combined organic solvents Were 
evaporated to dryness under reduced pressure. The resulting 
residue Was puri?ed by column chromatography (hexanes: 
ethyl acetate 10:1) to afford 2.63 g of 1,3,5-tris-(5-bro 
mopent-1-ynyl)-benZene. Yield 89%. 1H NMR (300 MHZ, 
CDCl3) 6 7.33 (s, 3H), 3.57 (t, 1:63 HZ), 2.60 (t, 1:69 HZ, 
6H), 2.12 (m, 6H) ppm; 13C NMR (75 MHZ, CDCl3) 6 133.9, 
124.1, 89.2, 80.4, 32.6, 31.7, 18.4 ppm. 
Example 3 
Preparation of 1 ,3 ,5 -tris -(5 -hydroxypentyl) -b enZene 
HO % % OH 
H —’ 
OH 
HO OH 
OH 
1,3,5 -tris-(5 -hydroxy-1-pentynyl)-benZene (2. 84 g, 8 .6 
mmol) Was dissolved in methanol (30 mL) and 10% Pd/C (5% 
W/W) Was added. The resulting mixture Was hydrogenated on 
a Parr hydrogenation apparatus (45 psi) for 4 hours. The 
catalyst Was removed by ?ltration through a celite pad. The 
?lter cake Was rinsed With methanol, and the combined 
organic liquors Were concentrated under reduced pressure. 
The crude product Was puri?ed by column chromatography 
(CHCl3:MeOH 6:1) to afford 2.84 g of 1 ,3,5-tris-(5-hydroxy 
pentyl)-benZene. Yield 96%. 1H NMR (300 MHZ, CDCl3) 6 
6.81 (s, 3H), 3.62 (t, 1:63 HZ, 6H), 2.57 (t, J:7.5 HZ, 6H), 
1.53-1.70 (m, 12H), 1.38 (m, 6H) ppm; 13C NMR (75 MHZ, 
CDCl3) 6 142.5, 126.1, 63.1, 36.1, 32.9, 31.5, 25.7 ppm. 
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Example 4 
Preparation of 1,3,5-tris-(5 -bromopentyl)-benZene 
HO OH 
Br 
Preparation of 1,3,5-tris-(5 -bromopentyl)-benZene 
1,3,5-tris-(5-hydroxypentyl)-benZene (2.83 g, 8.41 mmol) 
and carbon tetrabromide (10.99 g, 32.80 mmol) Were dis 
solved in dry methylene chloride (50 mL) and cooled to 0° C. 
Triphenyl phosphine (9.03 g, 34.33 mmol) Was added drop 
Wise and the mixture Was stirred for 30 minutes at 00 C. The 
mixture Was poured into hexanes (250 mL), ?ltered through a 
short silica gel column and Washed With ethyl acetate/hexanes 
(1/4). The combined organic solvents Were evaporated to 
dryness under reduced pressure. The resulting residue Was 
puri?ed by column chromatography (hexaneszethyl acetate 
8:1) to afford 4.08 g of 1,3,5-tris-(5-bromopentyl)-benZene. 
Yield 92%. 1H NMR (300 MHZ, CDCl3) 6 6.81 (s, 3h), 3.41 
(t, J:6.9 HZ, 6H), 2.60 (t, 1:75 HZ, 6H), 1.88 (m, 6H), 1.45 
(m, 6H) ppm; 13C NMR (75 MHZ, CDCl3) 6 142.4, 126.1, 
35.9, 34.2, 32.9, 30.9, 28.2 ppm. 
Example 5 
Preparation of 
1,3, 5-tris-[5-(2 -picolinium)-pent-1 -ynyl] -benZene 
tribromide 
Br % % Br 
—> 
Br 
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(9 -continued (9 
/ 
\ \ 
6 ll 3Br 
(9 
N/ I 
A mixture of 1,3,5-tris-(5-bromopent-1-ynyl)-benZene 
(223 mg, 0.43 mmol) and 2-picoline (607 mg, 6.52 mmol) 
Was heated at 60-700 C. for 12 hours. The resultant mixture 
Was Washed With diethyl ether and then dissolved in Water (15 
mL), the aqueous solution Was Washed With diethyl ether, 
then lyophiliZed to afford 327 mg of 1,3,5-tris-[5-(2-pi 
colinium)-pent-1-ynyl]-benZene tribromide. Yield 95%. H 
NMR (300 MHZ, CD3OD) 6 9.01 (dd, 1:63, 0.9 HZ, 3H), 
8.44 (dt, J:7.8, 1.5 HZ, 3H), 7.92-8.07 (m, 6H), 7.41 (s, 3H), 
4.81 (t, 1:60 HZ), 2.98 (s, 9H), 2.70 (t, J:7.2 HZ, 6H), 2.29 
(m, 6H) ppm; 13C NMR (75 MHZ, CD3OD) 6 157.1, 146.8, 
146.6, 134.9, 131.6, 127.1, 125.4, 90.1, 81.6, 58.4, 299,207, 
17.3 ppm. 
Example 6 
Preparation of 
1,3,5-tris-[5-(3-picolinium)-pent-1-ynyl]-benZene 
tribromide 
Br % % Br 
—> 
Br 
(*3 ® 
/ N N / I % f 
\ 
G l l 3 Br 
@ 
N / I 
\ 
A mixture of 1,3 ,5 -tris-(5 -bromopent-1-ynyl)-benZene 
(256 mg, 0.50 mmol) and 3-picoline (690 mg, 7.50 mmol) 
Was heated at 60-700 C. for 12 hours. The resultant mixture 
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Was Washed With diethyl ether (30 mL><3) and then dissolved 
in Water (15 mL), the aqueous solution Was Washed With 
diethyl ether, then lyophiliZed to afford 345 mg of 1,3,5-tris 
[5-(3-picolinium)-pent-1-ynyl]-benZene tribromide. Yield 
87%. 1H NMR (300 MHZ, CD3OD) 6 9.02 (s, 3H), 8.92 (d, 
J:6.0 HZ, 3H), 8.4 (d, J:8.4 HZ, 3H), 8.01 (dd, 1:81, 6.0 HZ, 
3H), 7.35 (s, 3H), 4.81 (t, J:7.2 HZ, 6H), 2.64 (t, 1:69 HZ, 
6H), 2.58 (s, 9H), 2.35 (m, 6H) ppm; 13C NMR (75 MHZ, 
CD3OD) 6 147.5, 145.8, 143.4, 141.3, 134.9, 128.8, 125.3, 
89.9, 81.5, 62.2, 31.0, 18.7, 17.2 ppm. 
Example 7 
Preparation of 
1,3, 5-tris-[5-(4 -picolinium)-pent-1 -ynyl] -benZene 
tribromide 
Br Br // \\ 
Br 
A mixture of 1,3,5-tris-(5-bromopent-1-ynyl)-benZene 
(210 mg, 0.41 mmol) and 4-picoline (572 mg, 6.14 mmol) 
Was heated at 60-700 C. for 12 hours. The resultant mixture 
Was Washed With diethyl ether and then dissolved in Water (1 5 
mL), the aqueous solution Was Washed With diethyl ether (30 
mL><3), then lyophiliZed to afford 316 mg of 1 ,3,5-tris-[5-(4 
picolinium)-pent-1 -ynyl] -benZene tribromide.Yield 97%. 1H 
NMR (300 MHZ, CD3OD) 8.91 (dd, 1:51, 1.8 HZ, 6H), 7.94 
(d, 1:63 HZ, 6H), 4.77 (t, 1:69 HZ, 6H), 2.63 (t, 1:66 HZ, 
6H), 2.62 (s, 9H), 2.33 (m, 6H) ppm; 13C NMR (75 MHZ, 
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@3013) 6 161.5, 145.2, 134.9, 130.0, 125.4, 90.0, 81.4, 61.6, 
30.8, 22.2, 17.2 ppm. 
Example 8 
Preparation of 1,3 ,5 -tris- [5 -(3 -butyl-pyridinium) 
pent-1 -ynyl] -benZene tribromide 
Br % % Br 
N 
Br 
(13 ® 
/ 11 % ¢ 11/ 
\ \ 
3% 
II I 
I'Z/ 
\ | 
A mixture of 1,3,5-tris-(5-bromopent-1-ynyl)-benZene 
(240 mg, 0.47 mmol) and 3-butyl pyridine (950 mg, 7.05 
mmol) Was heated at 60-700 C. for 12 hours. The resultant 
mixture Was Washed With diethyl ether and then dissolved in 
Water (15 mL), the aqueous solution Was Washed With diethyl 
ether (30 mL><3), then lyophiliZed to afford 254 mg of 1,3,5 
tris-[5-(3 -butyl-pyridinium) -pent- 1 -ynyl] -benZene tribro 
mide. Yield 59%. 1H NMR (300 MHZ, CD3OD) 6 9.04 (s, 
3H), 8.94 (d, 1:60 HZ, 3H), 8.44 (d, J:8.1 HZ, 3H), 8.04 (dd, 
1:81, 6.0 HZ, 3H), 7.33 (s, 3H), 4.82 (t, J:7.2 HZ, 6H), 2.87 
(t, J:7.8 HZ, 6H), 2.63 (t, 1:69 HZ, 6H), 2.35 (m, 6H), 1.69 
(m, 6H), 1.42 (m, 6H), 0.97 (t, 1:75 HZ, 9H) ppm; 13C NMR 
(75 MHZ, CD3OD) 6 146.8, 145.8, 145.6, 143.6, 135.0, 
129.0, 125.3, 89.9, 81.5, 62.2, 33.8, 33.5, 30.9, 23.5, 17.2, 
14.3 ppm. 
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Example 9 
Preparation of 1 ,3, 5 -tris - [ 5 - (3 -phenyl -pyridinium) - 
pent- 1 -ynyl] -benZene tribromide 
BI % % 
l l 
Br 
Br 
A mixture of 1,3,5-tris-(5 -bromopent-1-ynyl)-benZene 
(259 mg, 0.50 mmol) and 3-phenyl pyridine (1.18 g, 7.50 
mmol) Was heated at 60-700 C. for 12 hours. The resultant 
mixture Was Washed With diethyl ether and then dissolved in 
Water (15 mL), the aqueous solution Was Washed With diethyl 
ether (30 mL><5), then lyophiliZed to afford 415 mg of 1,3,5 
tris - [ 5 -(3 -phenyl-pyridinium) -p ent-1 -ynyl] -b enZene tribro - 
mide. Yield 85%. 1H NMR (300 MHZ, CD3OD) 6 9.50 (s, 
3H), 9.09 (d, 1:60 HZ, 3H), 8.78 (d, J:8.1 HZ, 3H), 8.16 (dd, 
1:81, 6.0 HZ, 3H), 7.75-7.87 (m, 6H), 7.42-7.65 (m, 9H), 
99,253 B2 
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40 7.17 (s, 3H), 4.96 (1, 1:69 HZ, 6H), 2.69 (1, 1:63 HZ, 6H), 
2.42 (m, 6H) ppm; 13C NMR (75 MHZ, CD3OD) 0 144.4, 
144.3,144.2,1426,134.9,134.5,131.5,130.8,129.5,128.7, 
125.1, 90.0, 81.5, 62.6, 30.8, 17.4 ppm. 
45 Example 10 
Preparation of 1,3,5-tris-{5-[3-(1-methyl-2-S-pyrro 
lidinyl)pyridinium] -p ent-1 -ynyl} -benZene tribromide 
Br // \\ 
Br 
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28 
A mixture of 1,3,5-tris-(5-bromopent-1-ynyl)-benZene 
(246 mg, 0.48 mmol) and S-nicotine (1.5 mL) Was heated at 
60-700 C. for 12 hours. The resultant mixture Was Washed 
With diethyl ether and then dissolved in Water (15 mL), the 
aqueous solution Was Washed With diethyl ether (30 mL><5), 
then lyophiliZed to afford 440 mg of 1,3,5-tris-{5-[3-(1-me 
thyl-2- S -pyrrolidinyl)pyridinium] -p ent-1 -ynyl} -benZene tri 
bromide.Yield 92%. 1H NMR (300 MHZ, CD3OD) 6 9.16 (s, 
3H), 9.02 (d, 1:60 HZ, 3H), 8.60 (d,j:8.1 HZ, 3H), 8.12 (dd, 
J:8.1, 6.0 HZ, 3H), 7.40 (s, 3H), 4.86 (t, 1:69 HZ, 6H), 3.69 
(m, 3H), 3.32 (m, 6H), 2.14-2.70 (m, 12H), 2.33 (s, 9H), 
1.73-2.14 (m, 10H) ppm; 13C NMR (75 MHZ, CD3OD) 6 
146.2, 145.4, 145.0, 135.1, 129.5, 125.3, 89.8, 81.8, 68.8, 
62.3, 58.0, 40.8, 36.0, 30.8, 24.1, 17.1 ppm. 
Example 11 
Preparation of 
1,3 ,5 -tris- [5 -(1-quinolinium)-pent-1-ynyl]-benZene 
tribromide 
Br Br // % 
Br 
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6 (B 
/ / F % 4 N 
\ 
9 
ll 3Br 
N/ 
\ 
A mixture of 1,3,5-tris-(5-bromopent-1-ynyl)-benZene 
(232 mg, 0.45 mmol) and quinoline (880 mg, 6.75 mmol) Was 
heated at 60-700 C. for 12 hours. The resultant mixture Was 
Washed With diethyl ether and then dissolved in Water (15 
mL), the aqueous solution Was Washed With diethyl ether (30 
mL><5), then lyophiliZed to afford 234 mg of 1,3,5-tris-[5-(1 
quinolinium)-pent-1-ynyl]-benZene tribromide. Yield 58%. 
1H NMR (300 MHZ, CD3OD) 6 9.58 (dd, 1:60, 4.5 HZ, 3H), 
9.18 (d, J:8.1 HZ, 3H), 8.67, d, 1:90 HZ, 3H), 8.41 (dd, 
1:81, 1.8 HZ, 3H), 8.31 (m, 3H), 7.98-8.18 (m, 6H), 7.11 (s, 
3H), 5.32 (t, 1:69 HZ, 6H), 2.75 (t, 1:66 HZ, 6H), 2.46 (m, 
6H) ppm; 13C NMR (75 MHZ, CD3OD) 6 150.9, 149.3, 
139.6,137.4,134.8,132.3,131.8,131.4,125.2,123.2,119.8, 
90.2, 81.4, 58.8, 29.6, 17.5 ppm. 
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eExample 12 
Preparation of 1,3,5-tris-[5-(2-isoquino1inium)-pent 
1 -yny1] -benZene tribromide 
Br % % Br 
I | 
Br 
G) (9 / / IN % % N 
\ \ 
9 l l 3 Br 
(9 
N / 
\ 
A mixture of 1,3,5-tris-(5 -bromopent-1-yny1)-benZene 50 Example 13 
(222 mg, 0.43 mmol) and isoquinoline (840 mg, 6.45 mmol) 
Was heated at 60-700 C. for 12 hours. The resultant mixture 
Was Washed With diethyl ether and then dissolved in Water (1 5 
Preparation of 1,3 ,5 -tris- [5 -(3 ,5 -1utidinium)-pent-1 
ynyl] -benZene tribromide 
mL), the aqueous so1ution Was Washed With diethyl ether (30 55 Br % % Br 
mL><5), then 1yoph111Zed to afford 357 mg of 1 ,3,5-tr1s-[5-(2 
isoquino1inium)-pent-1-yny1]-benZene tribromide. Yield 
92%.1H NMR (300 MHZ, CD3OD) 6 10.15 (s, 3H), 8.79 (dd, 
1:69, 1.2 HZ, 3H), 8.67, d, 1:90 HZ, 3H), 8.50 (m, 3H), 8.20 H 
(m, 6H), 8.06 (m, 3H), 6.54 (s, 3H), 5.00 (t, 1:69 HZ, 6H), 
2.75 (t, 1:63 HZ, 6H), 2.47 (m, 6H) ppm; 13C NMR (75 MHZ, 
CD3OD) 6 151.5, 139.2, 138.5, 136.0, 134.1, 132.6, 131.6, 
129.2, 128.4, 127.5, 124.7, 90.0, 81.2, 62.6, 30.5, 17.6 Br 















